[Growth hormone deficiency in adults: effects of replacement therapy on body composition and health-related quality of life].

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Deficiency of growth hormone (GH) in the adult is accompanied by changes in the body composition and a diminished health-related quality of life (HR-QoL).

The aim of the study was to assess the biochemical response to GH replacement therapy and its safety as well as the resulting body composition and HR-QoL.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A double-blind,randomized, placebo-controlled, 6-months study was first designed,then followed by a further 6-months period in which all patients received GH.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The body composition was determined by bioelectric impedanciometry and the HR-QoL was evaluated by the Nottingham Health Profile (NHP) and the QoL-AGHDA questionnaire.

What Was Measured

The subject headings attached to it are Body Composition, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism, Placebo Effect and Quality of Life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Medicina clinica), a journal based in Spain.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.